Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $92.01 in the prior trading day, Transmedics Group Inc (NASDAQ: TMDX) closed at $90.45, down -1.70%. In other words, the price has decreased by -$1.70 from its previous closing price. On the day, 0.91 million shares were traded. TMDX stock price reached its highest trading level at $92.3 during the session, while it also had its lowest trading level at $89.55.
Ratios:
Our goal is to gain a better understanding of TMDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 8.30. In the meantime, Its Debt-to-Equity ratio is 2.27 whereas as Long-Term Debt/Eq ratio is at 2.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when Khayal Tamer I sold 2,407 shares for $76.43 per share. The transaction valued at 183,967 led to the insider holds 36,042 shares of the business.
Gordon Stephen bought 5,942 shares of TMDX for $389,855 on Mar 04 ’25. On Jan 07 ’25, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 1,083 shares for $80.05 each. As a result, the insider received 86,694 and left with 20,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 3059733504 and an Enterprise Value of 3226397696. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 89.54, and their Forward P/E ratio for the next fiscal year is 40.22. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.93 while its Price-to-Book (P/B) ratio in mrq is 13.30. Its current Enterprise Value per Revenue stands at 7.307 whereas that against EBITDA is 56.352.
Stock Price History:
The Beta on a monthly basis for TMDX is 1.90, which has changed by -0.29330415 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 19.74%, while the 200-Day Moving Average is calculated to be -10.89%.
Shares Statistics:
The stock has traded on average 1.19M shares per day over the past 3-months and 1003590 shares per day over the last 10 days, according to various share statistics. A total of 33.62M shares are outstanding, with a floating share count of 32.58M. Insiders hold about 3.67% of the company’s shares, while institutions hold 108.14% stake in the company. Shares short for TMDX as of 1744675200 were 8782313 with a Short Ratio of 7.38, compared to 1741910400 on 9551242. Therefore, it implies a Short% of Shares Outstanding of 8782313 and a Short% of Float of 44.86.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Transmedics Group Inc (TMDX) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.34, with high estimates of $0.41 and low estimates of $0.3.
Analysts are recommending an EPS of between $1.8 and $1.27 for the fiscal current year, implying an average EPS of $1.5. EPS for the following year is $2.24, with 6.0 analysts recommending between $2.5 and $1.94.
Revenue Estimates
7 analysts predict $123.39M in revenue for the current quarter. It ranges from a high estimate of $130.3M to a low estimate of $115.4M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $96.85MFor the next quarter, 7 analysts are estimating revenue of $132.51M. There is a high estimate of $134.7M for the next quarter, whereas the lowest estimate is $131M.
A total of 8 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $543.66M, while the lowest revenue estimate was $536.86M, resulting in an average revenue estimate of $540.54M. In the same quarter a year ago, actual revenue was $441.54MBased on 9 analysts’ estimates, the company’s revenue will be $649.31M in the next fiscal year. The high estimate is $684.07M and the low estimate is $625M.
